Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

243 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

What to Expect From Bio-Techne's Q3 2026 Earnings Report

April 17, 2026 at 11:00 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company has a market cap of $9 billion and operates through two segments: Protein Sciences, Diagnostics and Spatial Biology.

TECH is expected to release its Q3 2026 earnings on Wednesday, May 6, before the market opens. Ahead of the event, analysts expect the company’s EPS to be $0.48 on a diluted basis, down 4% from $0.50 in the year-ago quarter. The company has met or exceeded Wall Street’s EPS estimates in each of its last four quarters.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

For fiscal 2026, analysts project the company’s EPS to be $1.73, up 1.2% from $1.71 in fiscal 2025. Moreover, its EPS is expected to rise by roughly 9.8% year over year (YoY) to $1.90 in fiscal 2027.

TECH stock has surged 23.5% over the past 52 weeks, underperforming the S&P 500 Index’s ($SPX) 34.7% rise but rallying the State Street Healthcare Select Sector SPDR ETF’s (XLV) 9.6% rise during the same time frame.

Bio-Techne has not been a champion in the eyes of investors, given its weak fundamentals. The company has experienced no organic revenue growth over the last two years, indicating a need to move towards acquisitions to drive growth. Moreover, TECH’s free cash flow margin decreased by 11.6% over the last five years, leading to a ramped-up capital intensity and requiring higher investment in operations, which could lead to a decline in its profit pool.

Analysts are moderately bullish on TECH, with the stock having a “Moderate Buy” rating overall. Among the 15 analysts covering the stock, 10 are recommending a “Strong Buy,” and five suggest a “Hold.” TECH’s average analyst price target is $72.25, indicating an upside of 21.2% from the current levels.

On the date of publication, Aritra Gangopadhyay did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article